title: Modulation of cell recruitment by anti-inflammatory agents in antigen-induced arthritis.
abstract: OBJECTIVE
  To study the effect of meloxicam (MXC) and diclofenac (DCF) on the recruitment of leucocytes during acute experimental arthritis.
  
  
  METHODS
  Rabbits with antigen-induced arthritis were treated with MXC, DCF, or not treated. After 48 hours, synovial fluid (SF) leucocyte influx and prostaglandin E(2) (PGE(2)) levels were evaluated. Interleukin 8 (IL8) and monocyte chemotactic peptide-1 (MCP-1) expression and synthesis were studied in the inflamed tissues.
  
  
  RESULTS
  Arthritic knees showed synovial effusion with a high leucocyte count and PGE(2) concentration, and an increased expression of IL8 and MCP-1. Both non-steroidal anti-inflammatory drugs (NSAIDs) reduced PGE(2) levels and the polymorphonuclear cell (PMN) concentration in SF, while the mononuclear cell (MN) concentration was unchanged in the treated groups in comparison with controls. A definite reduction of IL8 levels was obtained with the treatments, but the drugs did not prevent the up regulation of MCP-1.
  
  
  CONCLUSIONS
  The effect of these NSAIDs in acute arthritis may be related to the down regulation of IL8 production. The results suggest a differential effect of anti-inflammatory drugs on PMN and MN recruitment to the joint.
authors.affiliation: Inflammation Research Unit, Fundación Jiménez Díaz, Universidad Autónoma, Madrid, Spain.
authors.forename: M J
authors.initials: MJ
authors.lastname: López-Armada
authors.forename: O
authors.initials: O
authors.lastname: Sánchez-Pernaute
authors.forename: R
authors.initials: R
authors.lastname: Largo
authors.forename: I
authors.initials: I
authors.lastname: Diez-Ortego
authors.forename: I
authors.initials: I
authors.lastname: Palacios
authors.forename: J
authors.initials: J
authors.lastname: Egido
authors.forename: G
authors.initials: G
authors.lastname: Herrero-Beaumont
mesh_terms: D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D001169:Arthritis, Experimental / Q000188:drug therapy* / Q000276:immunology; D018932:Chemokine CCL2 / Q000235:genetics / Q000378:metabolism; D016861:Cyclooxygenase Inhibitors / Q000627:therapeutic use; D004008:Diclofenac / Q000627:therapeutic use*; D015232:Dinoprostone / Q000096:biosynthesis; D005786:Gene Expression Regulation / Q000187:drug effects; D016209:Interleukin-8 / Q000235:genetics / Q000378:metabolism; D007962:Leukocytes / Q000187:drug effects* / Q000276:immunology; D000077239:Meloxicam; D020556:Neutrophil Infiltration / Q000187:drug effects; D010047:Ovalbumin; D011817:Rabbits; D013843:Thiazines / Q000627:therapeutic use*; D013844:Thiazoles / Q000627:therapeutic use*
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D018932:Chemokine CCL2; D016861:Cyclooxygenase Inhibitors; D016209:Interleukin-8; D013843:Thiazines; D013844:Thiazoles; D004008:Diclofenac; D010047:Ovalbumin; D015232:Dinoprostone; D000077239:Meloxicam